Maternal fetal blood group incompatibility antibody adsorption therapeutic apparatus

Abstract

The invention relates to a maternal fetal blood group incompatibility antibody adsorption therapeutic apparatus in the field of medical science. The therapeutic apparatus is characterized in that Rh positive O-shaped red blood cells are cleaned by 4 DEG C and 37 DEG C normal saline and alternately washed by 25 and 35mmol/L of PB lysate with PH (potential of hydrogen) 7.4, D antigen containing ghost cells without hemoglobin are prepared, 80% cell concentration is formed by the aid of red blood cell storage solution with 3.5% mannitol, the ghost cells are placed in a cylindrical adsorber made of high-biocompatibility materials, sealed and stored at the temperature of 4 DEG C, and a screen is arranged at an outlet of the adsorber to form a defense line for preventing cell fragments from filtration. After plasma is filtered, Rh antibodies are combined into fixed complexes by the Rh positive red blood cells, the broken red blood cell fragments and macromolecular complexes formed by combination are intercepted by the screen of the adsorber, the plasma without morbid substances is filtered from the adsorber and then returned, and group incompatibility is treated by removing the Rh antibodies in the plasma.

Description

technical field [0001] The invention relates to a maternal-fetal blood group incompatibility antibody adsorption therapeutic apparatus in the medical field, which is mainly used for removing anti-fetal red blood cell antibodies and red blood cell lysates in plasma of pregnant women with maternal-fetal blood group incompatibility. Background technique [0002] The fetus inherits half of the genetic components of the father and half of the mother, and the fetal red blood cells can carry antigens from the father, showing that the blood type of the fetus is different from that of the mother. When the fetal red blood cells enter the mother's blood circulation, the mother's immune system is induced to produce antibodies, and the antibodies pass through the placenta and enter the fetal blood circulation system, combining with fetal red blood cells, causing fetal red blood cells to be destroyed, resulting in maternal-fetal blood group incompatibility hemolytic disease in fetuses and ...

AI Technical Summary

Problems solved by technology

However, plasma exchange can only remove part of the antibodies in the blood, and cannot stop the continuous production of antibodies, nor can it reverse the existing maternal-fetal blood group incompatibility hemolytic disease. It needs continuous plasma exchange to be effective. Pregnant women who had fetal hydrops two weeks ago, or whose spouses are homozygous for the pathogenic antigen, especially while removing part of the pathogenic antibody, also removed a large amount of plasma (multiple beneficial components), although the replacement fluid Supplementation has been made, but the removed plasma and its various beneficial components cannot be completely supplemented, and the replacement fluid for the replacement is large and expensive. Supplementing allogeneic plasma is prone to various side effects such as infectious diseases and infusion reactions, which limits plasma exchange. the general development of

Images